



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.**

**Citation for published version:**

Dwyer, BJ, Jarman, EJ, Gogoi-Tiwari, J, Ferreira-Gonzalez, S, Boulter, L, Guest, RV, Kendall, TJ, Thekkedath Kurian, D, Kilpatrick, AM, Robson, AJ, O'Duibhir, E, Man, TY, Campana, L, Starkey Lewis, PJ, Wigmore, SJ, Olynyk, JK, Ramm, GA, Tirnitz-Parker, JEE & Forbes, SJ 2020, 'TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.', *Journal of Hepatology*, vol. n/a, pp. 1-72. <https://doi.org/10.1016/j.jhep.2020.11.018>

**Digital Object Identifier (DOI):**

[10.1016/j.jhep.2020.11.018](https://doi.org/10.1016/j.jhep.2020.11.018)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Journal of Hepatology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression

Benjamin J. Dwyer<sup>1,2</sup>, Edward J. Jarman<sup>3</sup>, Jully Gogoi-Tiwari<sup>2</sup>, Sofia Ferreira-Gonzalez<sup>1</sup>, Luke Boulter,<sup>1,3</sup> Rachel V. Guest,<sup>1,9</sup> Timothy J. Kendall<sup>10</sup>, Dominic Kurian<sup>12</sup>, Alastair M. Kilpatrick<sup>1</sup>, Andrew J. Robson<sup>1</sup>, Eoghan O'Duibhir<sup>1</sup>, Tak Yung Man<sup>1</sup>, Lara Campana<sup>1</sup>, Philip J. Starkey Lewis<sup>1</sup>, Stephen J. Wigmore<sup>10,11</sup>, John K. Olynyk<sup>4,5</sup> Grant A. Ramm<sup>6,7</sup>, Janina E.E. Tirnitz-Parker<sup>2,8\*</sup>, Stuart J. Forbes<sup>1\*</sup>

## Affiliations:

<sup>1</sup>*Centre for Regenerative Medicine, Scottish Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK*

<sup>2</sup>*School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia*

<sup>3</sup>*MRC Human Genetics Unit, Western General Hospital Campus, Edinburgh, UK*

<sup>4</sup>*Department of Gastroenterology, Fiona Stanley Fremantle Hospital Group, Murdoch, WA, Australia*

<sup>5</sup>*School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia*

<sup>6</sup>*Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia*

<sup>7</sup>*QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia*

<sup>8</sup>*Centre for Cell Therapy and Regenerative Medicine, and School of Biomedical Sciences, University of Western Australia, Nedlands, WA, Australia.*

<sup>9</sup>*Department of Clinical Surgery, University of Edinburgh, Edinburgh EH16 4SA*

<sup>10</sup>*University of Edinburgh Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom*

<sup>11</sup>*Department of Surgery, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, United Kingdom*

<sup>12</sup>*The Roslin Institute & Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, United Kingdom*

\*Equal author contribution

**Correspondence:** Prof. Stuart J. Forbes, Director of Centre for Regenerative Medicine, Little France Drive, University of Edinburgh, Edinburgh bioQuarter, Edinburgh, United Kingdom, EH16 4UU. E-mail: stuart.forbes@ed.ac.uk, Tel: +44(0)1316519510, Fax: +44(0)1316519501.

**Keywords:** Cholangiocarcinoma, Liver cancer, TWEAK, Fn14, Tumour-associated macrophage, Cancer-associated fibroblast

**Electronic word count (Abstract, Main Text, References, Tables, Figure Legends) :** 6568 words

**Number of figures and tables:** 7 figures, 19 supplementary figures, 4 supplementary tables

**Author disclosures:** S.J.F. is supported by funds from Wellcome Trust, Medical Research Council, UKRMP and Syncona Ltd.

**Financial support:** This study was supported by grants from the National Health and Medical Research Council of Australia (APP1031330, APP1087125 and APP1061332) and the Alan Morement Memorial Fund (AMMF) charity.

**Author contributions:** Conceptualisation and design (B.D., E.J., S.F-G., R.V.G., L.B., J.T.P., S.J.F). Data generation (B.D., E.J., S.F-G., T.K., J.G-T., T-Y. M, A.M.K., L.B., R.V.G., A.R., D.K.), Data analysis and interpretation (B.D., J.G-T.,T.K., L.B., R.V.G., L.C., E.O.D., A.M.K., P.S-L., J.T.P., S.J.F.). Manuscript preparation (B.D., J.T.P, S.J.F). Review and editing (B.D., J.T.P., J.K.O., G.A.R., S.J.F). Funding acquisition (J.T.P., J.K.O., G.A.R., S.J.F).

**Data availability:** Mass spectrometry data was deposited on the MassIVE repository (<https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp>, accessible at Proteome Exchange (<http://www.proteomexchange.org/>; Accession:PXD015317). All other data are available upon reasonable request.

## ABSTRACT

**Background & Aims:** Cholangiocarcinoma (CCA) is a cancer of the hepatic bile ducts that is rarely resectable and associated with poor prognosis. New therapeutic strategies are urgently required. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is known to signal via its receptor fibroblast growth factor-inducible 14 (Fn14) and induce cholangiocyte and myofibroblast proliferation in liver injury. Its role in CCA remains undefined.

**Methods:** The expression of TWEAK ligand and Fn14 receptor was assessed immunohistochemically and by bulk RNA and single cell transcriptomics of human liver tissue. Spatiotemporal dynamics of pathway regulation were comprehensively analysed in rat and mouse thioacetamide (TAA)-mediated CCA. Flow cytometry, qPCR and proteomic analyses of CCA cell lines and conditioned medium experiments with primary macrophages were performed to evaluate TWEAK/Fn14 downstream functions. *In vivo* pathway manipulation was assessed via TWEAK overexpression in NICD/AKT-induced CCA or genetic Fn14 knockout during TAA-mediated carcinogenesis.


**Results:** Our data reveal TWEAK and Fn14 overexpression in multiple human CCA cohorts, and Fn14 upregulation in early TAA-induced carcinogenesis. TWEAK regulated the secretion of factors from CC-SW-1 and SNU-1079 CCA cells, inducing polarisation of pro-inflammatory CD206<sup>+</sup> macrophages. Pharmacological blocking of the TWEAK downstream target chemokine monocyte chemoattractant protein 1 (MCP-1) significantly reduced CCA xenograft growth, while TWEAK overexpression drove cancer-associated fibroblast proliferation and collagen deposition in the tumour niche. Genetic Fn14 ablation significantly reduced inflammatory, fibrogenic and ductular responses during carcinogenic TAA-mediated injury.

**Conclusion:** These novel data provide evidence for the action of TWEAK/Fn14 on macrophage recruitment and phenotype, and cancer-associated fibroblast proliferation in CCA. Targeting TWEAK/Fn14 and its downstream signals may provide a means to inhibit CCA niche development and tumour growth.

**Lay summary:** Cholangiocarcinoma is an aggressive, chemotherapy-resistant liver cancer. Interactions between tumour cells and cells that form a supportive environment for the tumour to grow are a source of this aggressiveness and resistance to chemotherapy. Herein, we describe interactions between tumour cells and their supportive environment via a chemical messenger, TWEAK and its receptor Fn14. TWEAK/Fn14 alters the recruitment and type of immune cells in tumours, increases the growth of cancer-associated fibroblasts in the tumour environment, and is a potential target to reduce tumour formation.

## Graphical abstract:

### Graphical abstract.



## INTRODUCTION

Cholangiocarcinomas (CCA) are aggressive hepatic malignancies, typically adenocarcinomas morphologically resembling hepatobiliary epithelium, expressing cytokeratins (CK) CK7 and CK19 but not CK20 or Hep-Par1[1-3]. CCA occurs at all regions of the biliary tree and is classified according to anatomical location; intrahepatic (iCCA; 20%), peri-hilar (pCCA; 50-60%) or distal (dCCA; 20-30%)[3, 4]. CCA remains clinically challenging due to late-stage presentation, chemotherapy resistance, and high post-surgery recurrence [3]. Consequently, 5-year survival rates remain below 25% [5].

CCA develops a characteristic thick, fibrous stroma composed of  $\alpha$ -smooth muscle actin ( $\alpha$ SMA)-expressing cancer-associated fibroblasts (CAFs), tumour-associated macrophages (TAMs), neutrophils and vascular endothelial cells [3]. Stromal cells interact with neoplastic ducts via several signals including Wntless-related integration site (Wnt) [6, 7], Notch [8, 9], Platelet-Derived Growth Factor [10, 11], Stromal-Derived Factor-1/C-X-C chemokine receptor type-4 [12, 13] and numerous cytokines, to support growth, evasion of apoptosis and promote metastatic progression via modulation of protein kinase-B (AKT) and extracellular signal-regulated kinase (ERK) pathways [13-15]. CD14<sup>+</sup>/CD16<sup>+</sup> peripheral blood monocytes are elevated in patients [16], and are recruited to tumour areas, where they differentiate into TAMs [17, 18]. TAM infiltration is correlated with tumour recurrence, metastasis and decreased survival [17, 19]. Fluorescently-tagged bone marrow-derived macrophages comprise the majority of CD206<sup>+</sup> TAMs in a rat CCA model, and secrete tumour-feeding Wnt ligands [7]. Ablating TAMs significantly reduces tumour formation, highlighting the importance of macrophage-derived factors in maintaining CCA [7].

1 The TNF-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14  
2 (Fn14) pathway acts via TWEAK ligand binding to its cognate receptor, Fn14, activating NF-  
3  $\kappa$ B/MAPK/PI3K/AKT downstream signalling [20] to regulate proliferation, survival,  
4 inflammation and angiogenesis. TWEAK is ubiquitously expressed in adult liver by  
5 macrophages, with signalling modulated by dynamic regulation of Fn14 during injury and  
6 repair [20, 21]. TWEAK initiates non-hepatocyte-mediated regeneration via canonical NF- $\kappa$ B-  
7 induced cholangiocyte proliferation [21, 22] and drives fibrosis-mediating hepatic stellate cell  
8 proliferation within the injury niche [23]. TWEAK-expressing macrophages were recently  
9 identified as key drivers of fibrosis, controlling Fn14<sup>+</sup> HSC proliferation in human cirrhotic  
10 liver [24]. TWEAK also stimulates proliferation of hepatocellular carcinoma cell lines [25],  
11 potentiating a role in liver cancer growth.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 We hypothesised that the principal role of TWEAK during chronic liver disease and CCA  
32 development may be two-fold: (i) to act as a canonical NF- $\kappa$ B pathway-driven mitogen  
33 controlling neoplastic duct and CAF proliferation and (ii) to induce NF- $\kappa$ B-driven chemotaxis-  
34 associated signalling during the establishment, maintenance and progression of CCA. We  
35 demonstrate that the TWEAK/Fn14 pathway is increasingly expressed during multi-species  
36 CCA development, regulating proliferation, migration and polarisation of cells, including  
37 macrophages and CAFs in the tumour niche, establishing TWEAK/Fn14 signalling as a novel,  
38 therapeutically targetable driver of CCA development.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## MATERIALS AND METHODS

### *Study approval*

Animal experiments were approved by the University of Edinburgh animal ethics committee with U.K. Home Office approval (70/7847, 70/8150, P231C5F81) or performed according to the Australian code for the care and use of animals for scientific purposes at Curtin University (AEC\_2014\_29). Retrospectively collected specimens were obtained from the National Health Service Lothian Scottish Academic Health Sciences Collaboration BioResource and healthy liver from the Edinburgh Medical Research Council Sudden Death Tissue Bank (10/H0716/3). Human blood was collected under ethical approval from the University of Edinburgh (15-HV-013). All human tissue samples were collected with informed consent.

All other methods can be found in the Supplementary Materials and Methods or the Supplementary CTAT Table.

## RESULTS

### *1. TWEAK and Fn14 upregulation in multi-species CCA*

We assessed Fn14 expression in archival CCA samples and interrogated publicly available mRNA expression data to ascertain whether the TWEAK/Fn14 pathway was overexpressed in CCA, and to define cell type interactions of ligand and receptor. In a cohort of pathologically confirmed human iCCA cases, Fn14 was highly expressed by malignant epithelia, localising at the surface of these cells. Lower expression was observed in bile ducts in surrounding liver (SL) areas of non-tumour liver tissue, with diffuse staining in hepatocytes. Fn14 was identifiable in endothelial cells within portal triads. Positive stromal cell staining consistent with CAFs was observed in a subset of samples (Figure 1A). Quantification confirmed



1 increased Fn14 expression in CCA versus non-CCA areas (Figure 1B), corroborated by  
2 interrogation of publicly available transcriptomic data. In a scRNA-seq dataset (GSE125449;  
3 [26]), *Fn14* was mainly expressed by malignant cells, and subsets of CAFs and hepatic  
4 progenitor cells (HPCs). *TWEAK* expression was mainly observed in a subset of TAMs in  
5 iCCA (Figure 1C). *Fn14* and *TWEAK* were significantly upregulated in tumour tissue versus  
6 non-involved liver in the TCGA-Chol cohort (Supplementary Figure 1A) and in a microarray  
7 dataset (GSE26566; [27]: Supplementary Figure 1B).

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20 We then assessed the distribution of Fn14 in PanCK<sup>+</sup> tumour epithelia and  $\alpha$ SMA<sup>+</sup> CAFs in an  
21 iCCA tissue microarray, where 42.50% of tumour cells (n=83 samples containing PanCK<sup>+</sup>  
22 cells) and 62.64% of CAFs (n=79 samples containing  $\alpha$ SMA<sup>+</sup> CAFs ) expressed Fn14 (Figure  
23 1D). We observed a greater proportion of Fn14<sup>+</sup> CCA cells in well-differentiated (grade 1)  
24 versus poorly differentiated (grade 3) iCCAs, but no association between tumour grade and the  
25 proportion of Fn14<sup>+</sup> CAFs (Figure 1D). No association was observed between TNM stage and  
26 proportion of Fn14<sup>+</sup> cells (Supplementary Figure 1C), supported by assessment of TCGA-Chol  
27 samples with respect to TNM stage (Supplementary Figure 1D).

28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43 Since archival human tissue samples represent end-stage CCA, we performed time course  
44 analyses to observe the temporal relationship of TWEAK/Fn14 expression to CCA  
45 development using rodent models of thioacetamide (TAA)-mediated injury (Figure 2A).  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Since archival human tissue samples represent end-stage CCA, we performed time course analyses to observe the temporal relationship of TWEAK/Fn14 expression to CCA development using rodent models of thioacetamide (TAA)-mediated injury (Figure 2A). Histological examination of Fn14-stained serial sections by a specialist liver histopathologist found that Fn14 was readily identifiable in dysplastic biliary lesions and early CCA (10-18 weeks; Supplementary Figure 2A). Similar to human data, Fn14 was observed at the cell surface of biliary lesions/CCA cells, some endothelial cells and transiently in damaged

1 hepatocytes (Supplementary figure 2). Fn14 was transiently upregulated in PanCK<sup>+</sup> ducts and  
2 surrounding damaged hepatocytes at 10 weeks (Figure 2B and Supplementary Figure 2A),  
3  
4 which reduced as injury progressed and more PanCK<sup>+</sup> cells were detected. As malignancy  
5 developed, subsets of PanCK<sup>+</sup> cells expressing Fn14 emerged. Fn14 expression continued in  
6  
7 CCA epithelia but not in non-malignant ducts (Figure 2B and Supplementary Figure 2B).  
8  
9 Biphasic Fn14 expression was mirrored transcriptionally, peaking at 10 and 20 weeks of TAA  
10  
11 treatment. *TWEAK* mRNA increased steadily over the time course (Figure 2C). Transcripts of  
12  
13 the pro-fibrotic markers collagen type 1 $\alpha$ 1, transforming growth factor- $\beta$ 1, tissue inhibitors of  
14  
15 metalloproteinases (*Timp1*, *Timp2*) and matrix metalloproteinases (*MMP2*, *MMP9*) exhibited  
16  
17 a comparable biphasic expression (Supplementary Figure 3).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 We assessed expression of TWEAK ligand and Fn14 receptor in a transgenic model of CCA  
29  
30 induction, where CCA develops during TAA treatment in livers with CK19-inducible Cre-  
31  
32 recombinase driven p53-deficiency, but not in mice with at least one functional p53 allele  
33  
34 (Figure 2D; [28]). TAA-treated K19-p53<sup>f/f</sup> mice significantly increased *TWEAK* and *Fn14*  
35  
36 mRNA and protein levels during CCA formation, compared to mice without CCA (K19-  
37  
38 p53<sup>flox/WT</sup> and K19-p53<sup>WT/WT</sup>; p53<sup>WT/het</sup>), measured by qPCR (Figure 2E) and Fn14 by western  
39  
40 blotting (Figure 2F).  
41  
42  
43  
44  
45

46 These data associate the transition of normal duct epithelium to iCCA with the upregulation of  
47  
48 TWEAK/Fn14 pathway and suggest a potential function during development and maintenance  
49  
50 in multi-species CCA.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2. *TWEAK/Fn14 modulates NF-κB-regulated cytokine/chemokine secretion in CCA cells*

To assess function of TWEAK/Fn14 in CCA epithelia, we studied the effects of recombinant human TWEAK (rhTWEAK) treatment in four well-characterised iCCA cell lines, all expressing cell surface Fn14 (Supplementary Figure 4A). TWEAK stimulation uniformly induced canonical p65 NF-κB phosphorylation, processing of non-canonical NF-κB p100 to p52 in CC-SW-1 and SNU-1079 cells (Figure 3A), and stimulated nuclear translocation of p65 in CCA cells (Figure 3B). Despite consistent rhTWEAK-mediated NF-κB activation in all cell lines, only SNU-1079 and HuH-28 cells displayed a mitogenic response to rhTWEAK (Figure 3C).

NF-κB regulates a variety of pro-inflammatory and pro-fibrogenic responses in liver disease [29]. Since a key element of CCA development is the formation of a stimulatory, pro-tumorigenic niche, we investigated TWEAK-induced gene expression changes in CCA cells. We observed TWEAK-inducible mRNA expression of *MCP-1* (3/4 cell lines), *CX<sub>3</sub>CL<sub>1</sub>* (3/4 cell lines), *IL-6* (1/4 cell lines), *IL-8* (3/4 cell lines), *M-CSF* (3/4 cell lines) and *GM-CSF* (2/4 cell lines) (Figure 3D). To determine pathway specificity, we assessed TWEAK-inducible gene expression in the presence and absence of inhibitors of canonical or non-canonical NF-κB signalling in CCA versus HCC cells. Generally, TWEAK-induced gene expression was subdued by canonical NF-κB inhibition in CCA lines. *IL-6* was inhibited by both inhibitors, whereas *CX<sub>3</sub>CL<sub>1</sub>* and *M-CSF* were not affected by either inhibitor in CC-SW-1 cells. Likewise, *CX<sub>3</sub>CL<sub>1</sub>* expression was not affected by either inhibitor in HuH-28 cells. TWEAK-induced gene expression was not observed in HepG2 HCC cells (Supplementary Figure 4B).

We observed significantly increased TWEAK-induced secretion of MCP-1 (all cell lines), IL-8 (2/4 cell lines) and GM-CSF (all cell lines) into the cell culture medium (Figure 3E). We also

1 characterised proteins present in conditioned medium from PBS- or TWEAK-treated cells by  
2 mass spectrometry. Secreted proteins that were present in both PBS- and TWEAK-treated cell  
3 line conditioned medium, or in TWEAK-treated conditioned medium alone, were assessed for  
4 protein-protein interactions and 'biological process' gene ontology (GO) enrichment  
5 (Supplementary Figures 5-8). Several GO terms associated with pro-tumour microenvironment  
6 development were enriched in TWEAK-conditioned medium, including extracellular matrix  
7 (ECM) development (ECM organisation), blood vessel development (angiogenesis, blood  
8 vessel remodelling/development) and immune modulation (regulation of  
9 leukocyte/macrophage chemotaxis, immune system process, immune response) in a cell line-  
10 specific manner.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 These cell line-specific results classified the investigated Fn14<sup>+</sup> iCCA lines as TWEAK-high  
26 responder (CC-SW-1 and SNU-1079) and TWEAK-low responder cell lines (CC-LP-1 and  
27 HuH-28) and provided evidence that TWEAK/Fn14 may play a role in the development of  
28 CCA by orchestrating the surrounding niche via localised NF-κB-mediated  
29 chemokine/cytokine secretion.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 ***3. TWEAK-induced CCA-derived factors regulate macrophage biology***

42  
43

44 Tumour-associated macrophages (TAMs) play a critical role in providing pro-proliferative and  
45 pro-survival factors in CCA [7]. Since TWEAK induces the secretion of several pro-  
46 inflammatory proteins in CCA cells, we investigated whether any of these TWEAK-induced,  
47 CCA-derived secreted proteins could affect macrophage phenotypes. To model the effect of  
48 TWEAK in CCA-induced patterning of macrophages in the CCA niche, we isolated human  
49 peripheral blood monocytes (Supplementary Figure 9A), differentiated these cells into  
50 macrophages (HMDMs) and subjected HMDMs to (a) PBS-supplemented basal medium  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

versus (b) TWEAK-supplemented basal medium, to assess the direct effects of TWEAK in HMDMs; or to (c) conditioned medium of 72 hours PBS-treated CCA cell lines versus (d) conditioned medium of 72 hours TWEAK-treated CCA cell lines, to measure the indirect effects of TWEAK in HMDMs via TWEAK-induced protein secretion in the CCA cell lines.

HMDM differentiation was confirmed by 25F9 expression (Supplementary Figure 9B). Treatment with conditioned medium from TWEAK-stimulated TWEAK-high responder CCA lines (CC-SW-1 and SNU-1079) significantly increased cell surface expression of a TAM-associated marker, CD206, in HMDMs. No significant difference was observed when conditioned medium from TWEAK-low responder CCA lines (CC-LP-1 and HuH-28 cells) was used (Figure 4A), suggesting that TWEAK-induced factors from some CCA cells can induce macrophage polarisation. We also assessed mRNA expression of several cytokines, chemokines, growth factors and receptors. HMDMs expressed 154- to 733-fold less *Fn14* mRNA than CCA/HCC cell lines (Supplementary Figure 9C) and did not modulate gene expression when treated with TWEAK alone (Figure 4B). Few genes were differentially regulated in HMDMs exposed to conditioned medium from the TWEAK-low responder CCA cells (*MMP-2* in TWEAK-conditioned medium from CC-LP-1 cells, and *TWEAK* and *CD163* mRNA in TWEAK-conditioned medium from HuH-28 cells). However, expression of several key transcripts was induced in HMDMs treated with TWEAK-conditioned medium from CC-SW-1 and SNU-1079 cells. *IL-6* was upregulated in TWEAK-conditioned medium from both cell lines (82.6-fold and 105.2-fold), and *TIMP-1* (4.5-fold and 4.3-fold). In CC-SW-1 conditioned medium-patterned cells, we observed additional upregulation of *CD80* (2.8-fold), *M-CSF* (6.2-fold) and *TNF* (3.9-fold). SNU-1079-patterned cells responded with additional upregulation of *MCP-1* (4.0-fold) and vascular endothelial growth factor-alpha (*VEGF-α*; 4.5-fold). We also assessed two surface markers associated with TAMs; triggering receptor expressed on myeloid cells 2 (*TREM-2*) and macrophage receptor with collagenous structure

(*MARCO*). All populations expressed *TREM-2*, and SNU-1079-patterned cells upregulated *MARCO* (18.1-fold; Figure 4B).

#### ***4. MCP-1 is upregulated in CCA and affects macrophage accumulation in the tumour niche***

MCP-1 was the most abundant TWEAK-inducible protein produced by CCA cell lines (Figure 2). In addition, MCP-1 was upregulated in macrophages by TWEAK-inducible factors produced by CCA cells (Figure 4). We therefore further investigated MCP-1 expression in CCA to link in vitro observations to human disease. In analysis of a scRNA-seq dataset (GSE125449; [26]), *MCP-1* mRNA was expressed by CAFs, and subsets of tumour cells, HPCs and TAMs, while cognate receptor *CCR2* was mainly expressed in TAMs and T cells (Supplementary Figure 10A). We observed increased MCP-1 immunostaining in archival human iCCA in tumour epithelia and widespread expression in stromal cells, compared to a subset of paired non-involved surrounding liver areas (Figure 5A), confirmed by pixel analysis (Figure 5B).

Next, we assessed the co-regulation of the TWEAK/Fn14 pathway and MCP-1 expression in CCA epithelia. We stratified PanCK<sup>+</sup> epithelial tumour cells into Fn14<sup>+</sup> and Fn14<sup>-</sup> subsets, assessed the distribution of MCP-1<sup>+</sup> cells in iCCA and further assessed these data with respect to tumour grade (Figure 5C). Importantly, MCP-1 expression was proportionally higher in Fn14<sup>+</sup> versus Fn14<sup>-</sup> iCCA ducts in this cohort (Figure 5D; n=89). When stratified by tumour grade, this distribution was maintained in moderately differentiated grade 2 tumours (p<0.0001, n=32;) and poorly differentiated grade 3 tumours (p=0.0014, n=44; Figure 5D). This preferential distribution of MCP-1<sup>+</sup> cells to Fn14<sup>+</sup> tumour epithelia was also observed in our cohort of archival sections of iCCA patients and another commercially available CCA

tissue microarray (Supplementary Figure 10B), suggesting an active TWEAK/Fn14/MCP-1 axis in a significant proportion of CCAs across three independent cohorts.

We further assessed MCP-1 protein expression in two key components of the tumour niche; TAMs (CD68<sup>+</sup>) and CAFs ( $\alpha$ SMA<sup>+</sup>). MCP-1 was expressed by 18.26% of CD68<sup>+</sup> TAMs and 18.52% of CAFs compared to 27.98% of malignant epithelia in this cohort of tumours (n=88-90; Figure 5E). Having confirmed MCP-1 upregulation in clinical samples, we explored the temporal modulation and functional significance of MCP-1 upregulation during CCA development in rodent models.

In rat CCA, small clusters of MCP-1<sup>+</sup> cells were detected during early tumour development (Figure 6A). MCP-1 was expressed specifically in PanCK<sup>+</sup> epithelia in tumour niches containing large areas of accumulated TAMs (CD68<sup>+</sup>; Figure 6B). *MCP-1* mRNA also exhibited the bi-phasic expression observed for *Fn14*, increasing again after peak *Fn14* expression was observed during tumour formation (Figure 6C). MCP-1 was also expressed by CCA tumour cells in our previously described transgenic TAA CCA model [28] (Figure 6D), suggesting a critical, conserved role for MCP-1 during multi-species CCA development.

To investigate the functional role of MCP-1 in recruiting macrophages to the CCA niche, we performed pharmacological blocking experiments using SNU-1079-generated human CCA cell xenografts (Figure 6E). Mice receiving multiple injections of anti-MCP-1 antibody formed significantly smaller tumours (Figure 6F), with 2.3-fold fewer intra-tumoral F4/80<sup>+</sup> macrophages (Figure 6G), and 2.2-fold fewer CD206<sup>+</sup> macrophages (Figure 6G), compared to control antibody-treated xenografts. We observed significantly more circulating MCP-1 receptor (CCR2<sup>+</sup>) monocytes in anti-MCP-1-treated animals (Figure 6H). Although

subcutaneous xenografts do not recapitulate the entire liver microenvironment, they enable modelling of interactions between circulating immune cells and human CCA cells. Thus, these data provide a key functional context of the role of MCP-1 expression in CCA with in vivo evidence that recruitment of tumour-associated macrophages occurs via chemoattraction of CCR2<sup>+</sup> monocytes.

## 5. TWEAK signalling modulation affects tumour formation in vivo

To characterise the effects of TWEAK on CCA tumour development, we used a previously described system of NICD and AKT overexpression in hepatocytes to induce CCA in six weeks (combination referred to as NICD/AKT, [30]). We compared tumours in this model to NICD/AKT tumours overexpressing TWEAK (combination referred to as NICD/AKT+TWEAK). The construct used to overexpress TWEAK also expressed red fluorescent protein (RFP), facilitating concurrent assessment of the localisation of TWEAK-overexpressing cells (Supplementary Figure 11A). Macroscopic white, cyst-like lesions were observed on the surface of NICD/AKT livers (Figure 7A and Supplementary Figure 12A), analogous to previously published observation [30]. TWEAK overexpression produced striking alterations in the appearance of livers, with sizeable bile-containing cysts observed on the surface (Figure 7A, Supplementary Figure 12B).

Microscopic histological characterisations of tumours using blinded assessment by an independent, specialist liver histopathologist revealed features that were consistent with this model [30]; tumours consisted of multifocal nodular lesions, often coalescing, precluding quantification of tumour number. Tumours were variably cystic and micropapillary epithelial neoplasms with cytological epithelial features in keeping with malignancy, with TWEAK overexpression increasing the cystic content of these tumours (Figure 7B, Supplementary



Figure 11B). Formal observer-independent quantification of tumour elements showed that TWEAK overexpression increased the total tumour area and cystic percentage of tumours (Figure 7C). The tumour epithelial area was not altered by TWEAK overexpression (Figure 7C). Accordingly, CK19<sup>+</sup> epithelium with active, nuclear localisation of phosphorylated NF- $\kappa$ B p65 in either bile duct or CCA tissue was similar in both conditions (Figure 7D), and most CCA cells were proliferating (Ki67<sup>+</sup>; Figure 7E), presumably as a result of AKT overexpression [30]. We did not find an association between the tumour cystic grade and the proportion of Fn14<sup>+</sup> cells in CCA cells or CAFs in patient tissues (Supplementary Figure 13).

Complementing our xenograft results, we observed increases in innate immune cells with TWEAK overexpression, including CD11b<sup>+</sup> monocyte/neutrophils that clustered within the tumour niche in cystic tumour areas (Supplementary Figure 11C), and a 2-fold increase in CD206<sup>+</sup> macrophage numbers (Supplementary Figure 11C). In addition, GM-CSF was upregulated in liver and plasma with TWEAK overexpression (Supplementary Figure 11D).

TWEAK overexpression also significantly affected the CAF subcompartment of the CCA niche, previously shown to express Fn14<sup>+</sup> in patient iCCAs (Figure 1). We detected a 1.32-fold increase in the  $\alpha$ SMA<sup>+</sup> CAF area and the Picrosirius Red-positive collagen area in NICD/AKT+TWEAK tumours (Figure 7F). TWEAK activation of canonical NF- $\kappa$ B signalling, demonstrated by an increased proportion of CAFs expressing nuclear phospho-p65 (Figure 7G), has previously been shown to drive hepatic stellate cell proliferation in chronic liver injury [23]. We observed a 1.53-fold increase in proliferating Ki67<sup>+</sup>/ $\alpha$ SMA<sup>+</sup> CAFs in TWEAK-overexpressing CCAs (Figure 7G).

Having established novel roles of TWEAK in inflammatory and fibrogenic niche development in CCA, critical components of a tumour-permissive environment [31], we assessed TAA-mediated chronic liver disease in homozygous Fn14 knockout mice compared to wildtype Fn14-expressing littermate controls (Supplementary Figure 14A). Following six months of TAA injury, significant macroscopic tumour formation was observed in Fn14 wildtype mice (12/12 animals with one or multiple tumours; 2, <2 mm; 9, 2-5 mm, 1, >5 mm diameter), while 1/9 Fn14 knockout mice displayed an early tumour of less than 2 mm in diameter (Supplementary Figure 14B). Concomitant with tumour inhibition in Fn14 knockout mice, we observed a reduction in PanCK<sup>+</sup> cells as well as F4/80<sup>+</sup> and CD206<sup>+</sup> macrophages (Supplementary Figure 14C, 14D). MCP-1, GM-CSF, IL-6 and KC/Gro remained at steady-state levels in 6-month TAA-treated mice (Supplementary Figure 14E). These data support our hypothesis that TWEAK/Fn14 signalling plays a pivotal role in niche establishment during chronic liver injury, capable of supporting hepatic tumour development.

## DISCUSSION

During chronic liver injury, macrophage-produced TWEAK drives proliferation of Fn14<sup>+</sup> cholangiocytes to initiate hepatic regeneration [21, 22, 32] and  $\alpha$ SMA<sup>+</sup> myofibroblasts, affecting extracellular matrix deposition in damaged liver areas by regulating their cell numbers [23, 24]. Macrophages comprise the majority inflammatory cell infiltrate in the CCA stroma [15-17, 19], providing key signals such as Wnt ligands to induce growth and apoptosis resistance [6, 7], and cytokines including IL-6, TNF and TGF- $\beta$ 1 to promote metastatic progression [15, 17]. We hypothesised that TWEAK/Fn14-induced downstream signalling represents a significant pathway, supporting CCA growth and maintenance.

Through corroboration of transcriptomic data from multiple independent CCA patient cohorts and characterisation of patient samples, we demonstrated upregulation of Fn14 in CCA, on tumour epithelial cells and CAFs, compared to non-involved liver tissue. Significantly, a subset of TWEAK-expressing TAMs localised within the CCA niche, suggesting interplay between ligand-expressing niche and receptor-expressing tumour/niche via TWEAK/Fn14, potentiating therapeutic targeting. We demonstrated that TWEAK/Fn14 pathway elements are progressively upregulated in rodent CCA tissues. Previous studies reported proliferation of biliary epithelial, and HCC cells, in response to TWEAK [21, 22, 25, 32]. We explored the effects of TWEAK in CCA lines, and found TWEAK elicited NF- $\kappa$ B signalling modulations in all investigated CCA cell lines, but not HepG2 HCC cells. However, this signal led to cell line-specific cellular responses, suggesting more complex functions for TWEAK/Fn14 signalling in CCA.

In chronic injury, NF- $\kappa$ B controls the expression of a multitude of chemokines and growth factors that regulate liver inflammation and repair, including MCP-1 [33], while aberrant expression of NF- $\kappa$ B pathway components results in spontaneous liver fibrosis and eventual HCC in genetic mouse models [34-36]. Although TWEAK-responsive NF- $\kappa$ B pathway activation was seen in all CCA cell lines we assessed, we did not observe consistent proliferative effects, as reported in other liver cell types [21, 22, 25]. In response to TWEAK stimulation, CCA cells secreted proinflammatory chemokines and growth factors, suggesting TWEAK can regulate CCA niche development. We further explored the functional role of MCP-1, which drives inflammatory macrophage recruitment to sites of liver injury via its receptor CCR2 [37, 38]. Disrupting MCP-1/CCR2 has proven effective in inhibiting TAM accumulation and tumour development in preclinical HCC models [39, 40]. We observed in vitro TWEAK-inducible MCP-1 expression and detected MCP-1 in tumour cells in multi-species CCA. MCP-1 inhibition reduced SNU-1079 xenograft size, with accumulation of

CCR2<sup>+</sup> monocytes in peripheral blood and decreased TAMs, providing evidence for an MCP-1-mediated macrophage recruitment to the tumour niche by CCA cells. Further support for this axis having a functional role is provided by our data from TAA-treated Fn14 knockout mice, which displayed significantly reduced macrophages and drastically inhibited or delayed tumorigenesis.

We also report a novel function of TWEAK in the liver in driving the secretion of factors from CCA cells that alter macrophage phenotype. CCA cells actively educated macrophages towards a TAM-like phenotype, expressing a mixture of classically activated and alternative activation markers, as well as upregulating molecules involved in matrix remodelling [18]. In TWEAK-high responsive CCA cell lines (SNU-1079 and CC-SW-1), we observed an increased ability to pattern macrophages towards a TAM-like ‘M2-skewed’ phenotype with CD206 and pro-inflammatory gene expression including IL-6, TNF and MCP-1, reminiscent of TAMs observed in CCA [7, 17, 19]. Additionally, CCA-patterned macrophages also upregulated the scavenger receptor MARCO, a marker of immunosuppressive TAMs in many tumour types [41]. Data from progressive CCA in rats demonstrated that Fn14 and MCP-1 upregulation is co-regulated early in CCA development. Furthermore, TWEAK overexpression in CCA promoted a dramatic tumour phenotype alteration by inducing expansion of collagen-producing CAFs, which we show to express Fn14 in a significant proportion of patient iCCAs. By driving inflammatory chemokine production, altering macrophage phenotype via crosstalk with CCA epithelia and promoting fibroblastic growth within the CCA microenvironment via a direct action of TWEAK on CAF proliferation, upregulation of TWEAK/Fn14 signalling appears to be an early driver, promoting the development of a niche that supports tumour growth. Our data using genetic knockout or antibody inhibition of TWEAK downstream events

1 highlight the potential for clinically relevant therapeutic targeting. A humanised antibody  
2 against TWEAK, RG7212, is currently being investigated for its efficacy in treating late stage  
3  
4 Fn14<sup>+</sup> solid tumours in malignancies including colorectal cancer, melanoma and a cohort of  
5  
6 three CCA patients, with antibody treatment well-tolerated. Noteworthy, one of the desired  
7  
8 actions of antibody treatment is to reduce serum MCP-1 levels [42, 43].  
9  
10

11  
12  
13  
14  
15  
16  
17 In addition to affecting the CAF and TAM niche compartments, we also report TWEAK-  
18  
19 induced secretion of molecules involved in blood vessel development and angiogenesis from  
20  
21 CCA cell lines. Macrophages patterned by TWEAK-inducible factors from SNU-1079 cells  
22  
23 also upregulated *VEGF-α* mRNA. Significantly, VEGF-A and VEGF-C from CAFs are  
24  
25 important mediators of lymphangiogenesis in CCA [44], which is correlated with poor patient  
26  
27 outcomes [45]. We also observed some vascular Fn14 expression in rat and human CCA.  
28  
29 TWEAK can stimulate endothelial cell proliferation, following Fn14 upregulation in response  
30  
31 to VEGF-A and FGF-2 [46]. Given our in vitro proteomic and macrophage patterning results,  
32  
33 combined with observation in patient samples, there is future scope to ascertain the role of  
34  
35 TWEAK/Fn14 signalling in metastatic progression by acting directly on endothelium, and  
36  
37 indirectly via secretion of proteins from tumour cells, tumour-conditioned TAMs and CAFs,  
38  
39 which promote tumour progression via pathways such as VEGF-A and VEGF-C.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 Our study provides a detailed and novel mechanistic framework of how the TWEAK/Fn14  
52  
53 pathway is involved in building a tumour-permissive niche, acting on TAMs and CAFs in  
54  
55 CCA, which both drive chemotherapy resistance [47]. Given the significant proportion of CCA  
56  
57 patients exhibiting aberrant upregulation of Fn14, targeting TWEAK/Fn14, may provide  
58  
59  
60  
61  
62  
63  
64  
65

avenues to interrupt epithelial-stromal crosstalk to create novel therapeutics for a cancer where effective treatments are urgently required.

**Abbreviations:** **AKT**- Protein Kinase B; **CAF**-Cancer-Associated Fibroblast; **CCA**-Cholangiocarcinoma; **CCR2**- C-C Chemokine Receptor type 2; **CK**- Cytokeratin; **CX3CL1**-(C-X3-C motif) Ligand 1; **ERK**- Extracellular Signal-Related Kinase; **Fn14**- Fibroblast Growth Factor-Inducible; **GM-CSF**- Granulocyte Macrophage Colony Stimulating Factor; **HCC**- Hepatocellular Carcinoma; **HMDM**- Human Monocyte-Derived Macrophage; **HPC**- Hepatic Progenitor Cell; **IL**- Interleukin; **MARCO**- Macrophage Receptor with Collagenous Structure; **MCP-1**- Monocyte Chemoattractant Protein 1; **M-CSF**- Macrophage Colony-Stimulating Factor; **MMP**- Matrix Metalloprotease; **NF**- Nuclear Factor; **NICD**- Notch Intracellular Domain; **SDF**- Stromal-Derived Factor; **TAA**- Thioacetamide; **TAM**- Tumour-Associated Macrophage; **TCGA**- The Cancer Genome Atlas; **TIMP**- Tissue Inhibitors of Metalloproteases; **TREM-2**- Triggering Receptor Expressed on Myeloid Cells-2; **TWEAK**- TNF-Like Weak Inducer of Apoptosis;  **$\alpha$ SMA**-  $\alpha$ -Smooth Muscle Actin

**Acknowledgements:** The authors acknowledge L. Burkly (Biogen) for providing Fn14 knockout mice. H. McGrath and A. Booth for help with animal experiments, R. Aird and I. Smith for technical assistance and F. Rossi and C. Cryer for flow cytometry assistance.

## REFERENCES

- [1] Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. *Hum Pathol* 2002;33:1175-1181.
- [2] Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. *Am J Surg Pathol* 2000;24:870-876.

- [3] Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nat Rev Gastroenterol Hepatol* 2020;17:557-588.
- [4] Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. *Nat Rev Clin Oncol* 2018;15:95-111.
- [5] Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. *JAMA Surg* 2014;149:565-574.
- [6] Loilome W, Bungkanjana P, Techasen A, Namwat N, Yongvanit P, Puapairoj A, et al. Activated macrophages promote Wnt/beta-catenin signaling in cholangiocarcinoma cells. *Tumour Biol* 2014;35:5357-5367.
- [7] Boulter L, Guest RV, Kendall TJ, Wilson DH, Wojtacha D, Robson AJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. *J Clin Invest* 2015;125:1269-1285.
- [8] Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. *J Clin Invest* 2012;122:3914-3918.
- [9] Guest RV, Boulter L, Dwyer BJ, Kendall TJ, Man TY, Minnis-Lyons SE, et al. Notch3 drives development and progression of cholangiocarcinoma. *Proc Natl Acad Sci U S A* 2016;113:12250-12255.
- [10] Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. *Hepatology* 2011;54:2076-2088.
- [11] Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, et al. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. *Hepatology* 2013;58:1042-1053.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [12] Ohira S, Sasaki M, Harada K, Sato Y, Zen Y, Isse K, et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. *Am J Pathol* 2006;168:1155-1168.
- [13] Gentilini A, Rombouts K, Galastri S, Caligiuri A, Mingarelli E, Mello T, et al. Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. *J Hepatol* 2012;57:813-820.
- [14] Okabe H, Beppu T, Ueda M, Hayashi H, Ishiko T, Masuda T, et al. Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. *Int J Cancer* 2012;131:2234-2241.
- [15] Techasen A, Loilome W, Namwat N, Dokduang H, Jongthawin J, Yongvanit P. Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells. *Asian Pac J Cancer Prev* 2012;13 Suppl:115-118.
- [16] Subimerb C, Pinlaor S, Lulitanond V, Khuntikeo N, Okada S, McGrath MS, et al. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. *Clin Exp Immunol* 2010;161:471-479.
- [17] Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. *Cancer Sci* 2010;101:1913-1919.
- [18] Raggi C, Correnti M, Sica A, Andersen JB, Cardinale V, Alvaro D, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. *J Hepatol* 2017;66:102-115.



- [19] Subimerb C, Pinlaor S, Khuntikeo N, Leelayuwat C, Morris A, McGrath MS, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. *Mol Med Rep* 2010;3:597-605.
- [20] Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. *Cytokine* 2007;40:1-16.
- [21] Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Kloplic BR, Olynyk JK, Yeoh GC, et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. *Hepatology* 2010;52:291-302.
- [22] Bird TG, Lu WY, Boulter L, Gordon-Keylock S, Ridgway RA, Williams MJ, et al. Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling. *Proc Natl Acad Sci U S A* 2013;110:6542-6547.
- [23] Wilhelm A, Shepherd EL, Amatucci A, Munir M, Reynolds G, Humphreys E, et al. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation. *J Pathol* 2016;239:109-121.
- [24] Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. *Nature* 2019.
- [25] Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. *Biochem Biophys Res Commun* 2004;318:726-733.
- [26] Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, et al. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. *Cancer Cell* 2019;36:418-430.e416.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [27] Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. *Gastroenterology* 2012;142:1021-1031.e1015.
- [28] Guest RV, Boulter L, Kendall TJ, Minnis-Lyons SE, Walker R, Wigmore SJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. *Cancer Res* 2014;74:1005-1010.
- [29] Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. *Hepatology* 2007;46:590-597.
- [30] Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. *J Clin Invest* 2012;122:2911-2915.
- [31] Guest RV, Boulter L, Dwyer BJ, Forbes SJ. Understanding liver regeneration to bring new insights to the mechanisms driving cholangiocarcinoma. *NPJ Regen Med* 2017;2:13.
- [32] Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. *J Clin Invest* 2005;115:2330-2340.
- [33] Marra F, Tacke F. Roles for chemokines in liver disease. *Gastroenterology* 2014;147:577-594 e571.
- [34] Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. *Cancer Cell* 2010;17:481-496.
- [35] Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. *Cancer Cell* 2007;11:119-132.

- [36] Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. *Proc Natl Acad Sci U S A* 2010;107:844-849.
- [37] Dambach DM, Watson LM, Gray KR, Durham SK, Laskin DL. Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. *Hepatology* 2002;35:1093-1103.
- [38] Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, et al. Hepatic recruitment of the inflammatory Gr1<sup>+</sup> monocyte subset upon liver injury promotes hepatic fibrosis. *Hepatology* 2009;50:261-274.
- [39] Teng KY, Han J, Zhang X, Hsu SH, He S, Wani NA, et al. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. *Mol Cancer Ther* 2017;16:312-322.
- [40] Li X, Yao W, Yuan Y, Chen P, Li B, Li J, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. *Gut* 2017;66:157-167.
- [41] Lopez-Yrigoyen M, Cassetta L, Pollard JW. Macrophage targeting in cancer. *Ann N Y Acad Sci* 2020.
- [42] Lassen UN, Meulendijks D, Siu LL, Karanikas V, Mau-Sorensen M, Schellens JH, et al. A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. *Clin Cancer Res* 2015;21:258-266.
- [43] Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, et al. Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. *Clin Cancer Res* 2016;22:858-867.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [44] Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. *J Hepatol* 2019;70:700-709.
- [45] Sha M, Jeong S, Wang X, Tong Y, Cao J, Sun HY, et al. Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma. *BMC Cancer* 2019;19:208.
- [46] Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. *Biochem Biophys Res Commun* 2002;299:488-493.
- [47] Cadamuro M, Brivio S, Spirli C, Joplin RE, Strazzabosco M, Fabris L. Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. *Int J Mol Sci* 2017;18.

## FIGURE LEGENDS

**Figure 1. TWEAK/Fn14 expression in cholangiocarcinoma (CCA).** (A) Fn14 immunohistochemistry in archival paraffin sections of patient-matched intrahepatic CCA (iCCA) versus non-involved areas of surrounding liver (SL; n=42 iCCA vs. n=26 SL) (B) Quantification of Fn14 immunostaining (Mann-Whitney U test). (C) Single cell RNA-sequencing data of iCCA (GSE125449; n=5 per cohort). Cell types: B-cells, cancer-associated fibroblasts (CAF), hepatic progenitor cells (HPC), malignant cells (Malig.), tumour-associated macrophages (TAM), T-cells, tumour endothelial cells (TEC), undefined. (D) Staining of Fn14 (red) in tumour cells (PanCK; white) and CAFs ( $\alpha$ SMA; green) in an iCCA tissue microarray. Nuclei are stained with DAPI (blue). Proportion of Fn14<sup>+</sup> tumour cells (n=84) and CAFs (n=74) by tumour grade (Kruskal-Wallis test with Dunn's multiple comparison test). Data are mean  $\pm$  SEM. \*p<0.05, \*\*p<0.01. Scale bars represent 100  $\mu$ m.

**Figure 2. TWEAK/Fn14 upregulation in rodent cholangiocarcinoma (CCA).** (A) Schematic of thioacetamide (TAA) treatment of rats to induce CCA. (B) Dual immunofluorescence reveals Fn14<sup>+</sup> (green) tumour epithelia (PanCK<sup>+</sup>; red). (C) mRNA expression of Fn14 and TWEAK in a time course of TAA treatment in rats (n=3 to 11; Kruskal-Wallis with Dunn's post-test) (D) Schematic of TAA treatment of Krt19-CreERTR26-eYFPp53<sup>flox/het/WT</sup> mice to induce CCA. (E) mRNA expression of Fn14 and TWEAK in Krt19-CreERTR26-eYFPp53<sup>Fl/WT</sup> or Krt19-CreERTR26-eYFPp53<sup>WT/WT</sup> (p53<sup>wt/het</sup>; no CCA, n=9) vs. Krt19-CreERTR26-eYFPp53<sup>flox/flox</sup> (p53<sup>f/f</sup>; CCA, n=6; Mann-Whitney U test). (F) Protein expression of Fn14 in mouse p53<sup>wt/het</sup> vs. p53<sup>flox/flox</sup> mice (n=7 each; unpaired t-test). Data are mean  $\pm$  SEM. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. Scale bars represent 50  $\mu$ m.

**Figure 3. TWEAK signalling drives NF- $\kappa$ B pathway activation and protein production.**

(A) TWEAK-dependent modulation of NF- $\kappa$ B pathway proteins in cholangiocarcinoma (CCA) cells and quantification of NF- $\kappa$ B protein expression 2h-post rhTWEAK exposure. (B) Localisation of NF- $\kappa$ B p65 subunit in CCA cell lines with TWEAK treatment. (C) MTT assay in CCA lines following 72 h treatment with increasing dose of rhTWEAK. (D) TWEAK-dependent mRNA expression in CCA lines following 6 h rhTWEAK treatment. (E) Protein immunoassay of secreted proteins from CCA lines treated with PBS or rhTWEAK. Data are mean  $\pm$  SEM. unpaired t-test (n=3) or one-way ANOVA with Dunnett's post-test (MTT assay; n=6); \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. Scale bars represent 50  $\mu$ m.

**Figure 4. Cholangiocarcinoma (CCA)-derived TWEAK-inducible factors drive macrophage patterning.**

(A) Cell surface CD206 expression (median fluorescence intensity; MFI) in HMDMs treated with conditioned medium (CM) from PBS- or TWEAK-treated CCA cells (One-way ANOVA with Tukey's post-test; n=3). (B) mRNA expression in HMDMs treated with conditioned medium from PBS- or TWEAK-treated CCA cells (n=3). Fold changes expression was calculated compared to control DMEM with PBS (DMEM+PBS) and analysed using one-way ANOVA with Dunnett's multiple comparison test. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. Data are mean  $\pm$  SEM.

**Figure 5. MCP-1 expression in cholangiocarcinoma (CCA).** (A) MCP-1 immunohistochemistry in archival paraffin sections of patient-matched intrahepatic CCA (iCCA) versus adjacent non-involved surrounding liver areas (SL). (B) Digital pixel analysis of sections (n=42 iCCA vs. n=26 SL; Mann-Whitney U test). (C) Staining of tumour liver tissue from an iCCA tissue microarray (n=89) with PanCK (white), Fn14 (red), MCP-1 (green). Nuclei are stained with DAPI (blue). (D) Analysis of total distribution of MCP-1<sup>+</sup> cells in Fn14<sup>-</sup> and Fn14<sup>+</sup> subsets of PanCK<sup>+</sup> tumour cells in individual CCA tissues or stratified with respect to tumour grade (Wilcoxon matched-pairs signed rank test). (E) Assessment of distribution in MCP-1<sup>+</sup> cells (red) in CD68<sup>+</sup> macrophages (green) and  $\alpha$ SMA<sup>+</sup> CAFs (white). Nuclei are stained with DAPI (blue). Data are mean  $\pm$  SEM. \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.0001. Scale bars represent 100  $\mu$ m.


**Figure 6. MCP-1 in rodent cholangiocarcinoma (CCA).** (A) MCP-1 immunohistochemistry (IHC) in liver from rats administered TAA for 10 weeks (injured, pre-malignant) up to 26 weeks. (B) Triple immunofluorescence reveals MCP-1<sup>+</sup> tumour epithelia (PanCK<sup>+</sup>) with interspersed macrophage infiltration (CD68) in rat CCA. (C) mRNA expression of MCP-1 in a time course of TAA treatment in rats (n=3-11 per timepoint; Kruskal-Wallis test with Dunn's post-test). (D) Triple immunofluorescence reveals MCP-1<sup>+</sup> tumour epithelia (PanCK<sup>+</sup>) with interspersed macrophage infiltration (F4/80<sup>+</sup>) in Krt19-CreERTR26-eYFPp53<sup>Fl/Fl</sup> mice administered TAA for 26 weeks to induce CCA. (E) Schematic of xenograft experiments. (F) SNU-1079 xenografts in CD-1 nude mice treated with control or anti-MCP-1 antibody (n=8 per group; unpaired t-test). (G) Macrophage marker (F4/80, CD206) staining of SNU-1079 xenografts (n=7 isotype vs. n=6 treated with anti-MCP-1; Mann-Whitney U test). (H) Analysis of peripheral blood monocytes of xenografted CD-1 nude mice (n=7 isotype vs. n=8 anti-MCP-

1 treated; unpaired t-test). Data are mean  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . Scale bars represent 50  $\mu\text{m}$ .

**Figure 7. TWEAK drives cancer-associated fibroblast (CAF) proliferation in cholangiocarcinoma (CCA).** CCA was induced in mice with overexpression of Notch Intra-Cellular Domain and AKT (NICD/AKT) with effects of TWEAK overexpression (NICD/AKT+TWEAK) assessed. (A) Gross morphology of livers. (B) Haematoxylin and eosin- stained liver sections. (C) Tumour area (Mann-Whitney U test) and cystic and tumour epithelial area quantification. (D) Staining of biliary tissue (CK19) and phosphorylated NF-kB p65 (p-p65) in normal and CCA areas. (E) Staining of biliary tissue and proliferation marker (Ki67). (F) Quantification of CAF ( $\alpha\text{SMA}^+$ ) area and collagen deposition (Picrosirius Red (PSR) staining). (G) Staining of CAF ( $\alpha\text{SMA}$ ) and p-p65 or proliferation marker (Ki67). Data are mean  $\pm$  SEM. \* $p < 0.05$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ . Unpaired t-test unless otherwise stated. Scale bars represent 100  $\mu\text{m}$ .



Figure 1.






**Figure 2.**


**A**

600 mg/l Thioacetamide (TAA)  
0 10 14 16 18 20 22 24 26  
weeks

**B**




**C**



**D**

CK19CreER<sup>T</sup>-YFP;Trp53<sup>f/f</sup>  
3xTM I.P. 600 mg/l TAA  
0 1 26  
weeks

**E**



**F**




Figure 3.






Figure 4.






Figure 5.








Figure 6.






**Figure 7.**



**Highlights:**

1. Fn14 is upregulated in on tumour cells and cancer associated fibroblasts, and TWEAK is expressed by tumour associated macrophages in human CCA. TWEAK/Fn14 are progressively upregulated during rodent tumour development, with Fn14 upregulated in dysplastic biliary lesions in pre-neoplastic liver in rats.
2. TWEAK/Fn14 signalling induces tumour associated macrophage accumulation via TWEAK-inducible MCP-1 chemotaxis which can be blocked in vivo.
3. TWEAK-inducible factors from tumour cells pattern macrophages to a TAM-like phenotype, upregulating CD206, and the expression of MCP-1, IL-6, TNF, VEGF- $\alpha$  and MARCO
4. TWEAK overexpression in experimental tumour formation drives CAF proliferation, collagen deposition and increases macrophages in mice, whilst tumour formation is reduced with genetic deletion of Fn14.








[Click here to access/download](#)

**Supplementary material**

Supplementary Material completed word cut.pdf





Click here to access/download  
**ICMJE disclosure form**  
COI forms.pdf